INTERVENTION 1:	Intervention	0
Pembrolizumab	Intervention	1
Participants received pembrolizumab 200 mg IV every Q3W for up to 35 administrations (up to ~2 years).	Intervention	2
INTERVENTION 2:	Intervention	3
Chemotherapy	Intervention	4
Participants received capecitabine, eribulin, gemcitabine, or vinorelbine as single agent chemotherapy chosen by the treating physician (Treatment of Physician's Choice, TPC) in accordance with local regulations and guidelines.	Intervention	5
capecitabine	CHEBI:31348	22-34
eribulin	CHEBI:63587	36-44
gemcitabine	CHEBI:175901	46-57
vinorelbine	CHEBI:480999	62-73
Inclusion Criteria:	Eligibility	0
Centrally confirmed Stage IV/M1 mTNBC	Eligibility	1
Newly obtained tumor biopsy from metastatic site	Eligibility	2
site	BFO:0000029	44-48
Central determination of programmed cell death ligand 1 (PD-L1) tumor status	Eligibility	3
central	HP:0030645	0-7
programmed cell death	GO:0012501	25-46
ligand	CHEBI:52214,GO:0005488	47-53
Received either one or two prior systemic treatments for metastatic breast cancer and have documented disease progression on or after the most recent therapy	Eligibility	4
breast cancer	DOID:1612	68-81
disease	DOID:4,OGMS:0000031	102-109
Previously treated with an anthracycline and/or taxane in the neoadjuvant/adjuvant or metastatic setting	Eligibility	5
anthracycline	CHEBI:48120	27-40
taxane	CHEBI:36064	48-54
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 10 days prior to study start	Eligibility	6
group	CHEBI:24433	29-34
Adequate organ function	Eligibility	7
organ	UBERON:0000062	9-14
function	BAO:0003117,BFO:0000034	15-23
Exclusion Criteria:	Eligibility	8
Participation in another clinical trial within 4 weeks	Eligibility	9
Monoclonal antibody (mAb) for direct anti-neoplastic treatment within 4 weeks	Eligibility	10
monoclonal	BAO:0000503	0-10
antibody	GO:0042571,BAO:0000502	11-19
Chemotherapy, targeted small molecule therapy, or radiation therapy within at least 2 weeks	Eligibility	11
small molecule	BAO:0000176	23-37
Active autoimmune disease that required systemic treatment in the past 2 years	Eligibility	12
active	PATO:0002354	0-6
autoimmune disease	DOID:417	7-25
Diagnosed with immunodeficiency or receiving systemic steroid therapy or another form of immunosuppressive therapy within 7 days	Eligibility	13
immunodeficiency	HP:0002721	15-31
steroid	CHEBI:35341	54-61
Known additional malignancy that required treatment or progressed in last 5 years	Eligibility	14
Known active brain metastases and/or carcinomatous meningitis	Eligibility	15
active	PATO:0002354	6-12
brain	UBERON:0000955	13-18
meningitis	HP:0001287,DOID:9471	51-61
Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-ligand-1 (anti-PD-L1), anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte associated protein 4 [CTLA-4], OX-40, CD137) or previously participated in any pembrolizumab (MK-3475) clinical studies	Eligibility	16
cell death	GO:0008219	38-48
receptor	BAO:0000281	163-171
protein	CHEBI:36080,BAO:0000175	212-219
Outcome Measurement:	Results	0
Overall Survival in Participants With Programmed Cell Death Ligand 1 (PD-L1) With Combined Positive Score (CPS) 10	Results	1
programmed cell death	GO:0012501	38-59
ligand	CHEBI:52214,GO:0005488	60-66
Overall survival (OS) was defined as the time from randomization to death due to any cause.	Results	2
time	PATO:0000165	41-45
death	OAE:0000632	68-73
Time frame: Up to approximately 36 months (through Final Analysis database cutoff date of 11-April-2019)	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Pembrolizumab	Results	5
Arm/Group Description: Participants received pembrolizumab 200 mg IV every Q3W for up to 35 administrations (up to ~2 years).	Results	6
Overall Number of Participants Analyzed: 96	Results	7
Median (95% Confidence Interval)	Results	8
median	BAO:0002174	0-6
Unit of Measure: Months  12.7        (9.9 to 16.3)	Results	9
Results 2:	Results	10
Arm/Group Title: Chemotherapy	Results	11
Arm/Group Description: Participants received capecitabine, eribulin, gemcitabine, or vinorelbine as single agent chemotherapy chosen by the treating physician (Treatment of Physician's Choice, TPC) in accordance with local regulations and guidelines.	Results	12
capecitabine	CHEBI:31348	45-57
eribulin	CHEBI:63587	59-67
gemcitabine	CHEBI:175901	69-80
vinorelbine	CHEBI:480999	85-96
Overall Number of Participants Analyzed: 98	Results	13
Median (95% Confidence Interval)	Results	14
median	BAO:0002174	0-6
Unit of Measure: Months  11.6        (8.3 to 13.7)	Results	15
Adverse Events 1:	Adverse Events	0
Total: 65/309 (21.04%)	Adverse Events	1
Anaemia 2/309 (0.65%)	Adverse Events	2
Febrile neutropenia 1/309 (0.32%)	Adverse Events	3
neutropenia	HP:0001875,DOID:1227	8-19
Neutropenia 1/309 (0.32%)	Adverse Events	4
neutropenia	HP:0001875,DOID:1227	0-11
Pancytopenia 0/309 (0.00%)	Adverse Events	5
pancytopenia	HP:0001876,DOID:12450	0-12
Thrombocytopenia 0/309 (0.00%)	Adverse Events	6
thrombocytopenia	HP:0001873,DOID:1588	0-16
Cardiac arrest 1/309 (0.32%)	Adverse Events	7
cardiac arrest	HP:0001695,DOID:0060319,OAE:0000461	0-14
Cardio-respiratory arrest 2/309 (0.65%)	Adverse Events	8
Cardiogenic shock 1/309 (0.32%)	Adverse Events	9
cardiogenic shock	HP:0030149	0-17
Sinus tachycardia 1/309 (0.32%)	Adverse Events	10
sinus tachycardia	HP:0011703	0-17
Secondary adrenocortical insufficiency 1/309 (0.32%)	Adverse Events	11
Adverse Events 2:	Adverse Events	12
Total: 60/292 (20.55%)	Adverse Events	13
Anaemia 2/292 (0.68%)	Adverse Events	14
Febrile neutropenia 5/292 (1.71%)	Adverse Events	15
neutropenia	HP:0001875,DOID:1227	8-19
Neutropenia 4/292 (1.37%)	Adverse Events	16
neutropenia	HP:0001875,DOID:1227	0-11
Pancytopenia 1/292 (0.34%)	Adverse Events	17
pancytopenia	HP:0001876,DOID:12450	0-12
Thrombocytopenia 1/292 (0.34%)	Adverse Events	18
thrombocytopenia	HP:0001873,DOID:1588	0-16
Cardiac arrest 0/292 (0.00%)	Adverse Events	19
cardiac arrest	HP:0001695,DOID:0060319,OAE:0000461	0-14
Cardio-respiratory arrest 0/292 (0.00%)	Adverse Events	20
Cardiogenic shock 0/292 (0.00%)	Adverse Events	21
cardiogenic shock	HP:0030149	0-17
Sinus tachycardia 0/292 (0.00%)	Adverse Events	22
sinus tachycardia	HP:0011703	0-17
Secondary adrenocortical insufficiency 0/292 (0.00%)	Adverse Events	23
